142 related articles for article (PubMed ID: 32321250)
1. Computational Investigation of APOBEC3H Substrate Orientation and Selectivity.
Hix MA; Cisneros GA
J Phys Chem B; 2020 May; 124(19):3903-3908. PubMed ID: 32321250
[TBL] [Abstract][Full Text] [Related]
2. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity.
Bohn JA; DaSilva J; Kharytonchyk S; Mercedes M; Vosters J; Telesnitsky A; Hatziioannou T; Smith JL
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578294
[TBL] [Abstract][Full Text] [Related]
3. Sequence and structural determinants of human APOBEC3H deaminase and anti-HIV-1 activities.
Mitra M; Singer D; Mano Y; Hritz J; Nam G; Gorelick RJ; Byeon IJ; Gronenborn AM; Iwatani Y; Levin JG
Retrovirology; 2015 Jan; 12():3. PubMed ID: 25614027
[TBL] [Abstract][Full Text] [Related]
4. Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability.
Feng Y; Love RP; Ara A; Baig TT; Adolph MB; Chelico L
J Biol Chem; 2015 Nov; 290(45):27188-27203. PubMed ID: 26396192
[TBL] [Abstract][Full Text] [Related]
5. The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.
Ooms M; Letko M; Binka M; Simon V
PLoS One; 2013; 8(2):e57744. PubMed ID: 23469063
[TBL] [Abstract][Full Text] [Related]
6. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
7. The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.
Ooms M; Majdak S; Seibert CW; Harari A; Simon V
J Virol; 2010 Aug; 84(16):7961-9. PubMed ID: 20519396
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Structure, Multimerization, Subcellular Localization and mC Selectivity of a Genomic Mutator and Anti-HIV Factor APOBEC3H.
Ito F; Yang H; Xiao X; Li SX; Wolfe A; Zirkle B; Arutiunian V; Chen XS
Sci Rep; 2018 Feb; 8(1):3763. PubMed ID: 29491387
[TBL] [Abstract][Full Text] [Related]
9. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.
Wang X; Abudu A; Son S; Dang Y; Venta PJ; Zheng YH
J Virol; 2011 Apr; 85(7):3142-52. PubMed ID: 21270145
[TBL] [Abstract][Full Text] [Related]
10. Recurrent Loss of APOBEC3H Activity during Primate Evolution.
Garcia EI; Emerman M
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925657
[TBL] [Abstract][Full Text] [Related]
11. Biochemical Characterization of APOBEC3H Variants: Implications for Their HIV-1 Restriction Activity and mC Modification.
Gu J; Chen Q; Xiao X; Ito F; Wolfe A; Chen XS
J Mol Biol; 2016 Nov; 428(23):4626-4638. PubMed ID: 27534815
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
Ooms M; Krikoni A; Kress AK; Simon V; Münk C
J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
[TBL] [Abstract][Full Text] [Related]
13. Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
Zhen A; Du J; Zhou X; Xiong Y; Yu XF
PLoS One; 2012; 7(7):e38771. PubMed ID: 22859935
[TBL] [Abstract][Full Text] [Related]
14. The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism.
Shaban NM; Shi K; Lauer KV; Carpenter MA; Richards CM; Salamango D; Wang J; Lopresti MW; Banerjee S; Levin-Klein R; Brown WL; Aihara H; Harris RS
Mol Cell; 2018 Jan; 69(1):75-86.e9. PubMed ID: 29290613
[TBL] [Abstract][Full Text] [Related]
15. RNA-Mediated Dimerization of the Human Deoxycytidine Deaminase APOBEC3H Influences Enzyme Activity and Interaction with Nucleic Acids.
Feng Y; Wong L; Morse M; Rouzina I; Williams MC; Chelico L
J Mol Biol; 2018 Dec; 430(24):4891-4907. PubMed ID: 30414963
[TBL] [Abstract][Full Text] [Related]
16. Human cytidine deaminase APOBEC3H restricts HIV-1 replication.
Dang Y; Siew LM; Wang X; Han Y; Lampen R; Zheng YH
J Biol Chem; 2008 Apr; 283(17):11606-14. PubMed ID: 18299330
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA.
Maiti A; Myint W; Kanai T; Delviks-Frankenberry K; Sierra Rodriguez C; Pathak VK; Schiffer CA; Matsuo H
Nat Commun; 2018 Jun; 9(1):2460. PubMed ID: 29941968
[TBL] [Abstract][Full Text] [Related]
18. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis.
Starrett GJ; Luengas EM; McCann JL; Ebrahimi D; Temiz NA; Love RP; Feng Y; Adolph MB; Chelico L; Law EK; Carpenter MA; Harris RS
Nat Commun; 2016 Sep; 7():12918. PubMed ID: 27650891
[TBL] [Abstract][Full Text] [Related]
19. The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H.
Wang J; Becker JT; Shi K; Lauer KV; Salamango DJ; Aihara H; Shaban NM; Harris RS
J Mol Biol; 2019 Dec; 431(24):5019-5031. PubMed ID: 31628948
[TBL] [Abstract][Full Text] [Related]
20. Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease.
Ebrahimi D; Richards CM; Carpenter MA; Wang J; Ikeda T; Becker JT; Cheng AZ; McCann JL; Shaban NM; Salamango DJ; Starrett GJ; Lingappa JR; Yong J; Brown WL; Harris RS
Nat Commun; 2018 Oct; 9(1):4137. PubMed ID: 30297863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
